Neuraxis Inc NRXS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
NeurAxis Reports Record Third Quarter 2026 Financial Results Driven by 150% Year Over Year Revenue Growth
NeurAxis to Host Third Quarter 2026 Results and Business Update Call on Monday, November 9, 2026
NeurAxis Announces Medical Policy Coverage Milestone, Expanding Access to 26 Million Additional Covered Lives
NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer
NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered Lives
NeurAxis to Participate in the Lytham Partners Fall 2026 Investor Conference
iAccess Alpha Virtual Best Ideas Fall Investment Conference Begins Today with Updated Presentation Schedule
iAccess Alpha Virtual Best Ideas Fall Investment Conference, September 15-16, 2026
Trading Information
- Previous Close Price
- $4.50
- Day Range
- $4.22–4.45
- 52-Week Range
- $2.21–9.33
- Bid/Ask
- $4.00 / $4.26
- Shares Outstanding
- 14.19M
- Market Cap
- $59.90M
- Volume/Avg
- 151,407 / 146,070
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 8.04
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 24
- Website
- https://www.neuraxis.com
Valuation
Metric | NRXS |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 17.17 |
Price/Sales | 8.04 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | NRXS |
|---|---|
Quick Ratio | 1.83 |
Current Ratio | 2.10 |
Interest Coverage | −186.60 |
Quick Ratio
NRXS
Profitability
Metric | NRXS |
|---|---|
Return on Assets (Normalized) | −78.91% |
Return on Equity (Normalized) | −136.20% |
Return on Invested Capital (Normalized) | −123.51% |
Return on Assets
NRXS
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|r^>$B#w | LOCK|N&d^R | $132B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|!!%BZX | LOCK|Xxm? | $96B | |||
| Moderna Inc MRNA | LOCK|!><!<# | LOCK|y@ | $81B | |||
| argenx SE ADR ARGX | LOCK|%%?>&%J | LOCK|Zz | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|XRwX&n | LOCK|&WW | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|!!j$zZ# | LOCK|^W$$? | $30B | |||
| Incyte Corp INCY | LOCK|SLkR%> | LOCK|>L | $24B | |||
| BioNTech SE ADR BNTX | LOCK|dRRz&n | LOCK|cL | $20B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|s><HCT | LOCK|H>x@? | $20B | |||
| BridgeBio Pharma Inc BBIO | LOCK|GF?%<w | LOCK|Qt | $15B |